Dabigatran faces new rival as rivaroxaban launched in Japan
This article was originally published in Scrip
Executive Summary
Bayer's oral Factor Xa inhibitor Xarelto (rivaroxaban) has received a reimbursement price and become the second novel anticoagulant to be launched in Japan for use in patients with atrial fibrillation.